Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brain Involvement in Dystrophinopathies Part 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04583917
Recruitment Status : Recruiting
First Posted : October 12, 2020
Last Update Posted : May 13, 2021
Sponsor:
Collaborators:
Newcastle-upon-Tyne Hospitals NHS Trust
Leiden University Medical Center
Stichting Kempenhaeghe
Region Hovedstadens Apotek
Institut Necker Enfants Malades
Catholic University of the Sacred Heart
Università degli Studi di Ferrara
Universidad Complutense de Madrid
Information provided by (Responsible Party):
Professor Francesco Muntoni, University College London Hospitals

Tracking Information
First Submitted Date October 5, 2020
First Posted Date October 12, 2020
Last Update Posted Date May 13, 2021
Actual Study Start Date March 30, 2021
Estimated Primary Completion Date February 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: October 5, 2020)
CNS Comorbidity Pheotyping [ Time Frame: 90 minutes ]
Correlate CNS comorbidity phenotypes with genotype in DMD and BMD patients
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Brain Involvement in Dystrophinopathies Part 1
Official Title Brain INvolvement in Dystrophinopathies (BIND): Deep Functional Phenotyping of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Patients (WP5) Part 1: a Multicentre Online Phenotyping and Neurobehavioural Data Collection Study
Brief Summary The objective of this study is to collect data from a large cohort of individuals with DMD and BMD focusing on the neurobehavioural aspects of these conditions and their correlation to the location of the DMD gene mutation.
Detailed Description

Intellectual disability and neurobehavioural comorbidities affect at least 50% of the individuals with Duchenne muscular dystrophy (DMD), which, although a rare genetic disease, is the most common form of muscular dystrophy in childhood. Several studies have documented that 25% of the DMD population has intellectual disability with recent studies suggesting that autism and clinically relevant hyperactivity affects 20% and 25% of DMD boys respectively. A milder allelic variant, named Becker muscular dystrophy (BMD), has similar prevalence in the population and is also associated with variable degrees of central nervous system (CNS) comorbidities, which however have been less well defined.

The investigators will address these deficiencies in a large multicentre study funded by the European Commission (EU H2020) involving 6 countries (Denmark; The Netherlands; France; Spain; Italy and UK) with the largest European neuromuscular centres and advocacy groups. The aim will be to study the neurobehavioural aspects of DMD and BMD as well as their correlation to the genotype. This study will involve male participants with DMD aged 5-17 years and with BMD aged 5-50 years. It will comprise of online questionnaires that will be completed either by a parent of a participant <17 years or an adult participant. The questionnaires take approximately 70 minutes to complete, however this can be done in multiple sittings. Currently there is a lack of information to assist the prognosis of CNS comorbidities, as existing databases and registries typically focus on the motor milestones and physical disability of these patients. There is therefore, an urgent need to present the course and outcomes in DMD and BMD patients with a wide range of DMD mutations, to provide information at the point of diagnosis and onwards for families, clinicians and service providers. It will also assist in paving the way to greater biological understanding and personalization of interventions.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Cross-Sectional
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients will be those followed in the two neuromuscular centres located in London and Newcastle; via the UK Clinical North Star network, the BIND website and the UK advocacy groups MDUK, Action Duchenne and Duchenne UK. A similar recruitment process will take place in the other EU countries, according to local regulations and after having obtained the relevant local ethical approval.
Condition
  • Duchenne Muscular Dystrophy
  • Becker Muscular Dystrophy
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: October 5, 2020)
800
Original Estimated Enrollment Same as current
Estimated Study Completion Date February 2023
Estimated Primary Completion Date February 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

For DMD patients:

  • Male
  • age 5-17 years
  • genetically-proven diagnosis of DMD
  • genetic mutation that abrogates expression of Dp427 alone (assigned in DMD Group 1: Dp427-/Dp140+) or both Dp427 and Dp140 (assigned to DMD Group 2: Dp427-/Dp140-); or all isoforms (assigned to DMD group 3)

For BMD patients:

  • age 5-50 years
  • genetically-proven diagnosis of BMD
  • genetic mutation that decreases expression of Dp427 alone (assigned to BMD Group 1), of both Dp427 and Dp140 (assigned to BMD Group 2), or of all the isoforms (assigned to BMD group 3).

Exclusion Criteria:

  • Lack of a molecular diagnosis of DMD or BMD
  • Mutation falls outside the regions of interest
  • A severe co-morbidity or planned surgical intervention within 6 months from the study which could interfere with the well-being of the participant
Sex/Gender
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
Gender Eligibility Description: DMD and BMD are sex-linked conditions, which occur predominantly in males.
Ages 5 Years to 50 Years   (Child, Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Francesco Muntoni 020 7905 2869 f.muntoni@ucl.ac.uk
Listed Location Countries Spain
Removed Location Countries  
 
Administrative Information
NCT Number NCT04583917
Other Study ID Numbers 20NM34
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Undecided
Plan Description: Pseudonymised data will be shared amongst collaborating partners in the project, but details on data sharing are still under discussion.
Responsible Party Professor Francesco Muntoni, University College London Hospitals
Study Sponsor University College London Hospitals
Collaborators
  • Newcastle-upon-Tyne Hospitals NHS Trust
  • Leiden University Medical Center
  • Stichting Kempenhaeghe
  • Region Hovedstadens Apotek
  • Institut Necker Enfants Malades
  • Catholic University of the Sacred Heart
  • Università degli Studi di Ferrara
  • Universidad Complutense de Madrid
Investigators
Principal Investigator: Francesco Muntoni University College, London
PRS Account University College London Hospitals
Verification Date May 2021